Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.

Asian Pacific journal of cancer prevention : APJCP - 1 Dec 2021

Hattakitpanitchakul Saroj, Kobbuaklee Sirorat, Wudhikarn Kitsada, Polprasert Chantana

Abstract excerpt

INTRODUCTION: Erythropoiesis stimulating agents (ESAs) represents the principal treatments for anemia in patients with lower-risk myelodysplastic syndromes (MDS). Pre-treatment erythropoietin (EPO) level and previous blood transfusion requirement are the two major predictors for response to ESAs. However, most evidence was derived from Western countries whereas there have been limited data in patients with Asian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Blood Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Aberrations

Share to Dioxygenases

Share to Erythropoietin

Share to Isocitrate Dehydrogenase

Share to Myelodysplastic Syndromes

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 34967586
DOI: 10.31557/APJCP.2021.22.12.4037
PMCID: PMC9080375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.PMID 34967586Read ↗

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read ↗

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialSemantic proximity Read ↗

Mutations and karyotype predict treatment response in myelodysplastic syndromes.Semantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndromeSemantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?Semantic proximity Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.Semantic proximity Read ↗

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes.Semantic proximity Read ↗

Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.